BioNTech SE Sponsored ADR $BNTX Stock Position Increased by Victory Capital Management Inc.

Victory Capital Management Inc. boosted its position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 97.0% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 413,685 shares of the company’s stock after buying an additional 203,700 shares during the period. Victory Capital Management Inc.’s holdings in BioNTech were worth $37,531,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. APG Asset Management N.V. raised its position in BioNTech by 3.0% in the third quarter. APG Asset Management N.V. now owns 54,700 shares of the company’s stock worth $5,395,000 after acquiring an additional 1,600 shares in the last quarter. Huntington National Bank boosted its position in shares of BioNTech by 1,266.7% during the 3rd quarter. Huntington National Bank now owns 410 shares of the company’s stock valued at $40,000 after purchasing an additional 380 shares in the last quarter. Fox Run Management L.L.C. grew its stake in shares of BioNTech by 242.8% in the 3rd quarter. Fox Run Management L.L.C. now owns 9,750 shares of the company’s stock worth $962,000 after purchasing an additional 6,906 shares during the last quarter. Optiver Holding B.V. acquired a new position in shares of BioNTech in the 3rd quarter worth approximately $198,000. Finally, Raiffeisen Bank International AG raised its holdings in shares of BioNTech by 52.4% in the 3rd quarter. Raiffeisen Bank International AG now owns 16,000 shares of the company’s stock worth $1,570,000 after purchasing an additional 5,500 shares in the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

BNTX has been the subject of several recent research reports. Leerink Partners lowered shares of BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 target price for the company. in a research note on Monday, February 2nd. Berenberg Bank reaffirmed a “buy” rating on shares of BioNTech in a report on Friday, January 23rd. HC Wainwright reiterated a “buy” rating and set a $140.00 price objective on shares of BioNTech in a research report on Thursday, December 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a research note on Friday, January 9th. Finally, UBS Group raised BioNTech to a “hold” rating in a research report on Thursday, December 4th. Eleven research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $140.10.

BioNTech Trading Down 0.4%

NASDAQ BNTX opened at $101.50 on Friday. The firm’s 50 day moving average price is $106.82 and its two-hundred day moving average price is $103.14. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.02 and a current ratio of 7.12. BioNTech SE Sponsored ADR has a twelve month low of $81.20 and a twelve month high of $124.00. The stock has a market cap of $22.86 billion, a price-to-earnings ratio of -38.59 and a beta of 1.51.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.